Skip to main content
SpringerLink
Log in

What Is Disease Progression?

  • Chapter
  • First Online:
Book cover Progressive Multiple Sclerosis

  • 1865 Accesses

Abstract

The clinical course of multiple sclerosis (MS) represents a spectrum. The subdivision of MS, according to the clinical course, has become increasingly important in recent years, since therapeutic clinical trials have shown demonstrable reductions in the frequency of clinical relapses and of inflammatory lesions as demonstrated on magnetic resonance imaging (MRI). Measures of disease progression are more resistant to change and in patients with progressive MS, it has been more difficult to demonstrate positive benefits from therapeutic interventions.

It has long been recognized that although patients may essentially share the diagnostic label of MS, there is considerable variation across a spectrum in terms of clinical phenotype, prognosis, MRI appearances, immunological characteristics, and pathology. The nature of the clinical course may also determine the response to disease-modifying therapy and the course itself may be influenced by underlying genetic heterogeneity.

In approximately 85–90% of cases, the onset of MS is marked by relapses and remissions—relapsing–remitting MS (RRMS). With time, an increasing proportion of these patients enter a secondary progressive phase (SPMS), 40% within 10 years and 65% within 25 years. SPMS represents a phase during which there are generally fewer relapses. It is characterized by gradual progression in disability. A minority of patients, 10–15%, do not have relapses at the onset of the disease, but rather, steadily accumulate disability over time. This has come to be described as primary progressive MS (PPMS).

How does the clinician know whether a patient with MS has progressive disease? In a similar way to the initial diagnosis of MS, although paraclinical measures and biomarkers (imaging and otherwise) can help, the diagnosis of progressive disease still remains firmly a clinical one. Neurologists will usually be able to classify the disease subtype of an individual patient based on clinical history and examination, although patients experiencing transition from relapsing–remitting MS to secondary progressive MS may be difficult to fully classify, as will patients experiencing significant numbers of relapses. In reality, disease progression is often not confidently diagnosed until time has passed in these patients and, thus, defining onset of disease progression is often a retrospective exercise.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. McDonnell GV, Hawkins SA. Clinical study of primary progressive multiple sclerosis in Northern Ireland, UK. J Neurol Neurosurg Psychiatry. 1998;64(4):451–4.

    Article  PubMed  CAS  Google Scholar 

  2. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996;46(4):907–11.

    Article  PubMed  CAS  Google Scholar 

  3. Polman CH, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292–302.

    Article  PubMed  Google Scholar 

  4. Mc AD, Compston N. Some aspects of the natural history of disseminated sclerosis. Q J Med. 1952;21(82):135–67.

    Google Scholar 

  5. Goodkin DE, et al. Low-dose oral methotrexate in chronic progressive multiple sclerosis: analyses of serial MRIs. Neurology. 1996;47(5):1153–7.

    Article  PubMed  CAS  Google Scholar 

  6. Hillert J, et al. An immunogenetic heterogeneity in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1992;55(10):887–90.

    Article  PubMed  CAS  Google Scholar 

  7. Weinshenker BG. Natural history of multiple sclerosis. Ann Neurol. 1994;36(Suppl):S6–11.

    Article  PubMed  Google Scholar 

  8. Filippi M, et al. Transitional progressive multiple sclerosis: MRI and MTI findings. Acta Neurol Scand. 1995;92(2):178–82.

    Article  PubMed  CAS  Google Scholar 

  9. Kremenchutzky M, et al. The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain. 2006;129(Pt 3):584–94.

    Article  PubMed  CAS  Google Scholar 

  10. Weinshenker BG. Progressive forms of MS: classification streamlined or consensus overturned? Lancet. 2000;355(9199):162–3.

    Article  PubMed  CAS  Google Scholar 

  11. Kremenchutzky M. The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation. Brain. 1999;122(Pt 10):1941–50.

    Article  PubMed  Google Scholar 

  12. Andersson PB, et al. Multiple sclerosis that is progressive from the time of onset: clinical characteristics and progression of disability. Arch Neurol. 1999;56(9):1138–42.

    Article  PubMed  CAS  Google Scholar 

  13. Allison RS, Millar JH. Prevalence of disseminated sclerosis in Northern Ireland. Ulster Med J. 1954;23 Suppl 2:1–27.

    PubMed  CAS  Google Scholar 

  14. Schumacker GA, et al. Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann N Y Acad Sci. 1965;122:552–68.

    Article  PubMed  CAS  Google Scholar 

  15. McDonald WI, Halliday AM. Diagnosis and classification of multiple sclerosis. Br Med Bull. 1977;33(1):4–9.

    PubMed  CAS  Google Scholar 

  16. Poser CM, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983;13(3):227–31.

    Article  PubMed  CAS  Google Scholar 

  17. McDonnell GV, Hawkins SA. Application of the Poser criteria in primary progressive multiple sclerosis. Ann Neurol. 1997;42(6):982–3.

    Article  PubMed  CAS  Google Scholar 

  18. Thompson AJ, et al. Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann Neurol. 2000;47(6):831–5.

    Article  PubMed  CAS  Google Scholar 

  19. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444–52.

    Article  PubMed  CAS  Google Scholar 

  20. Zeman AZ, et al. A study of oligoclonal band negative multiple sclerosis. J Neurol Neurosurg Psychiatry. 1996;60(1):27–30.

    Article  PubMed  CAS  Google Scholar 

  21. McDonald WI, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50(1):121–7.

    Article  PubMed  CAS  Google Scholar 

  22. Polman CH, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald criteria”. Ann Neurol. 2005;58(6):840–6.

    Article  PubMed  Google Scholar 

  23. Montalban X, et al. Primary progressive multiple sclerosis diagnostic criteria: a reappraisal. Mult Scler. 2009;15(12):1459–65.

    Article  PubMed  CAS  Google Scholar 

  24. Bonduelle M, Albaranes R. Statistical study of 145 cases of multiple sclerosis. Sem Hop. 1962;38:3762–73.

    PubMed  CAS  Google Scholar 

  25. Cottrell DA. The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. Brain. 1999;122(Pt 4):625–39.

    Article  PubMed  Google Scholar 

  26. Noseworthy J, et al. Multiple sclerosis after age 50. Neurology. 1983;33(12):1537–44.

    Article  PubMed  CAS  Google Scholar 

  27. Jeffery DR. Chronic progressive myelopathy: diagnostic analysis of cases with and without sensory involvement. J Neurol Sci. 1996;142(1–2):153–6.

    Article  PubMed  CAS  Google Scholar 

  28. Cazzullo CL, et al. Clinical picture of multiple sclerosis with late onset. Acta Neurol Scand. 1978;58(3):190–6.

    Article  PubMed  CAS  Google Scholar 

  29. Wingerchuk DM, et al. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6(9):805–15.

    Article  PubMed  CAS  Google Scholar 

  30. Wingerchuk DM, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66(10):1485–9.

    Article  PubMed  CAS  Google Scholar 

  31. O’Brien TJ, Gates PG, Byrne E. Symptomatic female heterozygotes for adrenoleukodystrophy: a report of two unrelated cases and review of the literature. J Clin Neurosci. 1996;3(2):166–70.

    Article  PubMed  Google Scholar 

  32. Wilkins A, et al. Very long chain fatty acid levels in patients diagnosed with multiple sclerosis. Mult Scler. 2009;15(12):1525–7.

    Article  PubMed  Google Scholar 

  33. Yu-Wai-Man P, et al. Inherited mitochondrial optic neuropathies. J Med Genet. 2009;46(3):145–58.

    Article  PubMed  CAS  Google Scholar 

  34. Camp SJ, et al. Cognitive function in primary progressive and transitional progressive multiple sclerosis: a controlled study with MRI correlates. Brain. 1999;122(Pt 7):1341–8.

    Article  PubMed  Google Scholar 

  35. Camp SJ, et al. A longitudinal study of cognition in primary progressive multiple sclerosis. Brain. 2005;128(Pt 12):2891–8.

    Article  PubMed  CAS  Google Scholar 

  36. Denney DR, Sworowski LA, Lynch SG. Cognitive impairment in three subtypes of multiple sclerosis. Arch Clin Neuropsychol. 2005;20(8):967–81.

    Article  PubMed  Google Scholar 

  37. Denney DR, et al. Cognitive impairment in relapsing and primary progressive multiple sclerosis: mostly a matter of speed. J Int Neuropsychol Soc. 2004;10(7):948–56.

    Article  PubMed  Google Scholar 

  38. Wachowius U, et al. Cognitive impairment in primary and secondary progressive multiple sclerosis. J Clin Exp Neuropsychol. 2005;27(1):65–77.

    Article  PubMed  Google Scholar 

  39. Weinshenker BG. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain. 1989;112(Pt 6):1419–28.

    Article  PubMed  Google Scholar 

  40. Confavreux C, et al. Relapses and progression of disability in multiple sclerosis. N Engl J Med. 2000;343(20):1430–8.

    Article  PubMed  CAS  Google Scholar 

  41. Weinshenker BG, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain. 1989;112(Pt 1):133–46.

    Article  PubMed  Google Scholar 

  42. Confavreux C, et al. Clinical progression and decision making process in multiple sclerosis. Mult Scler. 1999;5(4):212–5.

    PubMed  CAS  Google Scholar 

  43. Kurtzke JF. Clinical definition for multiple sclerosis treatment trials. Ann Neurol. 1994;36(Suppl):S73–9.

    Article  PubMed  Google Scholar 

  44. Fog T, Linnemann F. The course of multiple sclerosis in 73 cases with computer-designed curves. Acta Neurol Scand Suppl. 1970;47:3–175.

    PubMed  CAS  Google Scholar 

  45. Leray E, et al. Evidence for a two-stage disability progression in multiple sclerosis. Brain. 2010;133(Pt 7):1900–13.

    Article  PubMed  Google Scholar 

  46. Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain. 2003;126(Pt 4):770–82.

    Article  PubMed  Google Scholar 

  47. Debouverie M, et al. Natural history of multiple sclerosis in a population-based cohort. Eur J Neurol. 2008;15(9):916–21.

    Article  PubMed  CAS  Google Scholar 

  48. Vukusic S, Confavreux C. Natural history of multiple sclerosis: risk factors and prognostic indicators. Curr Opin Neurol. 2007;20(3):269–74.

    Article  PubMed  Google Scholar 

  49. Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain. 2006;129(Pt 3):606–16.

    Article  PubMed  Google Scholar 

  50. Confavreux C, Vukusic S. Age at disability milestones in multiple sclerosis. Brain. 2006;129(Pt 3):595–605.

    Article  PubMed  Google Scholar 

  51. Langdon DW. Cognition in multiple sclerosis. Curr Opin Neurol. 2011;24(3):244–9.

    Article  PubMed  Google Scholar 

  52. Bergendal G, Fredrikson S, Almkvist O. Selective decline in information processing in subgroups of multiple sclerosis: an 8-year longitudinal study. Eur Neurol. 2007;57(4):193–202.

    Article  PubMed  CAS  Google Scholar 

  53. Strober L, et al. Sensitivity of conventional memory tests in multiple sclerosis: comparing the Rao Brief Repeatable Neuropsychological Battery and the Minimal Assessment of Cognitive Function in MS. Mult Scler. 2009;15(9):1077–84.

    Article  PubMed  CAS  Google Scholar 

  54. Calabrese M, et al. Cortical pathology and cognitive impairment in multiple sclerosis. Expert Rev Neurother. 2011;11(3):425–32.

    Article  PubMed  Google Scholar 

  55. Laatu S, et al. Sematic memory deficit in multiple sclerosis; impaired understanding of conceptual meanings. J Neurol Sci. 1999;162(2):152–61.

    Article  PubMed  CAS  Google Scholar 

  56. Drew M, et al. Executive dysfunction and cognitive impairment in a large community-based sample with Multiple Sclerosis from New Zealand: a descriptive study. Arch Clin Neuropsychol. 2008;23(1):1–19.

    Article  PubMed  Google Scholar 

  57. Langdon DW, Thompson AJ. Multiple sclerosis: a preliminary study of selected variables affecting rehabilitation outcome. Mult Scler. 1999;5(2):94–100.

    PubMed  CAS  Google Scholar 

  58. Feinstein A. Mood disorders in multiple sclerosis and the effects on cognition. J Neurol Sci. 2006;245(1–2):63–6.

    Article  PubMed  Google Scholar 

  59. Chwastiak L, et al. Depressive symptoms and severity of illness in multiple sclerosis: epidemiologic study of a large community sample. Am J Psychiatry. 2002;159(11):1862–8.

    Article  PubMed  Google Scholar 

  60. Harel Y, Barak Y, Achiron A. Dysregulation of affect in multiple sclerosis: new phenomenological approach. Psychiatry Clin Neurosci. 2007;61(1):94–8.

    Article  PubMed  Google Scholar 

  61. Parmenter BA, Denney DR, Lynch SG. The cognitive performance of patients with multiple sclerosis during periods of high and low fatigue. Mult Scler. 2003;9(2):111–8.

    Article  PubMed  Google Scholar 

  62. Benedict RH, et al. Minimal neuropsychological assessment of MS patients: a consensus approach. Clin Neuropsychol. 2002;16(3):381–97.

    Article  PubMed  Google Scholar 

  63. Benedict RH, et al. Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). J Int Neuropsychol Soc. 2006;12(4):549–58.

    Article  PubMed  Google Scholar 

  64. Swingler RJ, Compston DA. The morbidity of multiple sclerosis. Q J Med. 1992;83(300):325–37.

    PubMed  CAS  Google Scholar 

  65. Kutzelnigg A, et al. Widespread demyelination in the cerebellar cortex in multiple sclerosis. Brain Pathol. 2007;17(1):38–44.

    Article  PubMed  Google Scholar 

  66. Craner MJ, et al. Annexin II/p11 is up-regulated in Purkinje cells in EAE and MS. Neuroreport. 2003;14(4):555–8.

    Article  PubMed  Google Scholar 

  67. Calabrese M, et al. Magnetic resonance evidence of cerebellar cortical pathology in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2010;81(4):401–4.

    Article  PubMed  Google Scholar 

  68. Anderson VM, et al. MRI measures show significant cerebellar gray matter volume loss in multiple sclerosis and are associated with cerebellar dysfunction. Mult Scler. 2009;15(7):811–7.

    Article  PubMed  CAS  Google Scholar 

  69. Davie CA, et al. Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss. Brain. 1995;118(Pt 6):1583–92.

    Article  PubMed  Google Scholar 

  70. Waxman SG. Cerebellar dysfunction in multiple sclerosis: evidence for an acquired channelopathy. Prog Brain Res. 2005;148:353–65.

    Article  PubMed  Google Scholar 

  71. Waxman SG. Acquired channelopathies in nerve injury and MS. Neurology. 2001;56(12):1621–7.

    Article  PubMed  CAS  Google Scholar 

  72. Kurtzke JF. Natural history and clinical outcome measures for multiple sclerosis studies. Why at the present time does EDSS scale remain a preferred outcome measure to evaluate disease evolution? Neurol Sci. 2000;21(6):339–41.

    Article  PubMed  CAS  Google Scholar 

  73. Willoughby EW, Paty DW. Scales for rating impairment in multiple sclerosis: a critique. Neurology. 1988;38(11):1793–8.

    Article  PubMed  CAS  Google Scholar 

  74. Amato MP, et al. Interrater reliability in assessing functional systems and disability on the Kurtzke scale in multiple sclerosis. Arch Neurol. 1988;45(7):746–8.

    Article  PubMed  CAS  Google Scholar 

  75. Francis DA, et al. An assessment of disability rating scales used in multiple sclerosis. Arch Neurol. 1991;48(3):299–301.

    Article  PubMed  CAS  Google Scholar 

  76. Goodkin DE. Inter- and intrarater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS). Multiple Sclerosis Collaborative Research Group. Neurology. 1992;42(4):859–63.

    Article  PubMed  CAS  Google Scholar 

  77. Hobart JC, et al. Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations. Lancet Neurol. 2007;6(12):1094–105.

    Article  PubMed  Google Scholar 

  78. Cohen JA, et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology. 2002;59(5):679–87.

    Article  PubMed  CAS  Google Scholar 

  79. Fischer JS, et al. The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment National MS Society Clinical Outcomes Assessment Task Force. Mult Scler. 1999;5(4):244–50.

    PubMed  CAS  Google Scholar 

  80. Cutter GR, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain. 1999;122(Pt 5):871–82.

    Article  PubMed  Google Scholar 

  81. Cohen JA, et al. Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial. Arch Neurol. 2001;58(6):961–7.

    Article  PubMed  CAS  Google Scholar 

  82. Miller DM, et al. Clinical significance of the multiple sclerosis functional composite: relationship to patient-reported quality of life. Arch Neurol. 2000;57(9):1319–24.

    Article  PubMed  CAS  Google Scholar 

  83. Kalkers NF, et al. MS functional composite: relation to disease phenotype and disability strata. Neurology. 2000;54(6):1233–9.

    Article  PubMed  CAS  Google Scholar 

  84. Goldman MD, Motl RW, Rudick RA. Possible clinical outcome measures for clinical trials in patients with multiple sclerosis. Ther Adv Neurol Disord. 2010;3(4):229–39.

    Article  PubMed  Google Scholar 

  85. Kragt JJ, et al. Responsiveness and predictive value of EDSS and MSFC in primary progressive MS. Neurology. 2008;70(13 Pt 2):1084–91.

    PubMed  CAS  Google Scholar 

  86. Kappos L, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet. 2007;370(9585):389–97.

    Article  PubMed  CAS  Google Scholar 

  87. Montalban X. Overview of European pilot study of interferon beta-Ib in primary progressive multiple sclerosis. Mult Scler. 2004;10 Suppl 1:S62; discussion 62–4.

    Article  PubMed  Google Scholar 

  88. Wolinsky JS, et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol. 2007;61(1):14–24.

    Article  PubMed  CAS  Google Scholar 

  89. Polman CH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899–910.

    Article  PubMed  CAS  Google Scholar 

  90. Kappos L, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387–401.

    Article  PubMed  CAS  Google Scholar 

  91. Goodman AD, et al. Fampridine-SR in multiple sclerosis: a randomized, double-blind, ­placebo-controlled, dose-ranging study. Mult Scler. 2007;13(3):357–68.

    Article  PubMed  CAS  Google Scholar 

  92. Hobart J, et al. The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. Brain. 2001;124(Pt 5):962–73.

    Article  PubMed  CAS  Google Scholar 

  93. Roxburgh RH, et al. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology. 2005;64(7):1144–51.

    Article  PubMed  CAS  Google Scholar 

  94. Briggs FB, et al. Genome-wide association study of severity in multiple sclerosis. Genes Immun. 2011;12(8):615–25.

    Google Scholar 

  95. Kister I, et al. Rapid disease course in African Americans with multiple sclerosis. Neurology. 2010;75(3):217–23.

    Article  PubMed  CAS  Google Scholar 

  96. Ebers GC. Commentary: outcome measures were flawed. BMJ. 2010;340:c2693.

    Article  PubMed  CAS  Google Scholar 

  97. Hobart J, et al. Outcome measures for multiple sclerosis clinical trials: relative measurement precision of the Expanded Disability Status Scale and Multiple Sclerosis Functional Composite. Mult Scler. 2004;10(1):41–6.

    Article  PubMed  CAS  Google Scholar 

  98. Hyland M, Rudick RA. Challenges to clinical trials in multiple sclerosis: outcome measures in the era of disease-modifying drugs. Curr Opin Neurol. 2011;24(3):255–61.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Royal Victoria Hospital, Belfast, UK

    Stanley Hawkins

  2. Department of Neurology, Frenchay Hospital, Frenchay Park Road, Bristol, BS16 1LE, UK

    Alastair Wilkins M.A., M.B., B.Chir, Ph.D., FRCP

Authors
  1. Stanley Hawkins
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alastair Wilkins M.A., M.B., B.Chir, Ph.D., FRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alastair Wilkins M.A., M.B., B.Chir, Ph.D., FRCP .

Editor information

Editors and Affiliations

  1. , Department of Neurology, Frenchay Hospital, Frenchay Park Road, Bristol, BS16 1LE, United Kingdom

    Alastair Wilkins

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag London

About this chapter

Cite this chapter

Hawkins, S., Wilkins, A. (2013). What Is Disease Progression?. In: Wilkins, A. (eds) Progressive Multiple Sclerosis. Springer, London. https://doi.org/10.1007/978-1-4471-2395-8_2

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-2395-8_2

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-2394-1

  • Online ISBN: 978-1-4471-2395-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation